Here’s a groundbreaking development that could revolutionize cancer treatment: IntoCell and Xcellon Biologics are joining forces to accelerate the creation of next-generation antibody-drug conjugates (ADCs). But here’s where it gets exciting—this partnership isn’t just about combining resources; it’s about merging cutting-edge chemistry with world-class manufacturing to make ADC technologies more accessible than ever before. On November 3, 2025, South Korean biotech innovator IntoCell announced a memorandum of understanding (MoU) with U.S.-based contract development and manufacturing organization (CDMO) Xcellon Biologics. The goal? To streamline the development and production of ADCs, a class of therapies that combine the precision of antibodies with the potency of drugs to target cancer cells more effectively.
At the heart of this collaboration is IntoCell’s proprietary OHPAS drug-linker system, which includes powerful payloads like Duocarmycin and Nexatecan. But here’s where it gets controversial—while ADCs hold immense promise, their complexity has historically slowed their development. Will this partnership truly bridge the gap? Xcellon will integrate OHPAS into its ADC development suite, enabling it to offer advanced bioconjugation and manufacturing services to pharma and biotech companies. This move not only expands Xcellon’s capabilities but also empowers researchers to explore a broader range of payload-linker combinations, potentially leading to more effective therapies.
IntoCell CEO Tae Kyo Park emphasized the synergy between the two companies, stating, ‘By combining our expertise, we aim to provide global innovators with the tools to bring differentiated ADC therapies to patients faster.’ Similarly, Xcellon COO and co-founder Yuk Chiu highlighted the partnership’s impact on innovation, noting, ‘This collaboration accelerates timelines and opens new doors for next-generation ADC programs.’
And this is the part most people miss—this partnership isn’t just about speeding up production; it’s about democratizing access to ADC research and development. Both companies share a vision of making these advanced therapies more widely available, which could transform the landscape of cancer treatment. Xcellon, operating as a subsidiary of Linden Lake Labs, specializes in complex biologics like T-cell engagers and bispecific antibodies, while IntoCell focuses on next-gen linker and payload solutions. Together, they’re creating a scalable model that supports projects from early discovery to investigational new drug applications.
As the pharmaceutical industry watches closely, one question remains: Will this collaboration set a new standard for ADC development, or will it face challenges that slow its progress? Let us know your thoughts in the comments below. And if you’re pushing the boundaries of innovation in pharma, don’t forget to nominate your work for the Pharmaceutical Technology Excellence Awards—it’s your chance to shine and join the ranks of industry leaders driving change.
